Sells CINVANTI, an intravenous medicine for preventing chemotherapy-related nausea and vomiting, and medicines for postsurgical pain and nausea to specialty distributors and wholesalers serving hospitals and healthcare providers.
10-K for FY2025, filed Feb 26, 2026CINVANTI is an IV formulation of aprepitant, a substance NK1 receptor antagonist. CINVANTI is the first IV formulation to directly deliver…View ↗
ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the…View ↗
APONVIE is the first and only intravenous formulation of aprepitant, a substance P/neurokinin-1 ("NK1") receptor antagonist indicated for…View ↗
Our Products are distributed in the U.S. through a limited number of specialty distributors and full line wholesalers that resell to…View ↗
CINVANTI is the largest product by revenue; Heron sells its medicines to specialty distributors and full-line wholesalers and gets paid when products are delivered.
10-K for FY2025, filed Feb 26, 2026
10-K for FY2025, filed Feb 26, 2026
FY2025 revenue by product or service ↗$154.9M
10-K for FY2025, filed Feb 26, 2026
$154.9M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
CINVANTI
Sold outright
10-K for FY2025, filed Feb 26, 2026 |
62%
FY2022: 81%
|
CINVANTI, FY2025
$96.8M Sources
|
Sold outright |
|
ZYNRELEF
Sold outright
10-K for FY2025, filed Feb 26, 2026 |
25%
FY2022: 9.5%
|
ZYNRELEF, FY2025
$38.1M Sources
|
Sold outright |
|
APONVIE
Sold outright
|
7.5% |
APONVIE, FY2025
$11.6M Sources
|
Sold outright |
|
SUSTOL
Sold outright
|
5.5%
FY2022: 9.5%
|
SUSTOL, FY2025
$8.5M Sources
|
Sold outright |
Heron sells to a limited number of specialty distributors and full-line wholesalers, which resell the medicines to healthcare providers and hospitals.
10-K for FY2025, filed Feb 26, 2026
No. It lost $20.2M in FY2025.
10-Q for Q3 FY2026, filed Nov 9, 2026
−$5MView ↗
10-Q for Q3 FY2026, filed Nov 9, 2026
Open tableView ↗
8-K, filed Nov 9, 2026
As previously announced, the Company withdrew its full-year 2026 financial guidance in August 2026. The Company is not providing financial…View ↗
8-K, filed Nov 9, 2026
Transaction expected to close in the first quarter of 2027, subject to regulatory clearance and approval by Heron stockholders and other…View ↗
8-K, filed Sep 29, 2026
On September 23, 2026 (the “Effective Date”), Heron Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a…View ↗
Growing. Revenue grew 79% in 4 years, from $86.3M in FY2021 to $154.9M in FY2025, about 16% a year.
SUSTOL commercialization
The latest report says Heron plans to wind down SUSTOL commercialization while evaluating product updates; the older report described SUSTOL as a marketed oncology product.
10-K for FY2022, filed Mar 29, 2023
ZYNRELEF indication
The latest report describes ZYNRELEF for soft-tissue and orthopedic procedures, whereas the older report listed a narrower set of specific surgeries.
10-K for FY2022, filed Mar 29, 2023 10-K for FY2025, filed Feb 26, 2026ZYNRELEF was initially approved by the FDA in May 2021, and we commenced commercial sales in the U.S. in July 2021. In December 2021, the…View ↗
ZYNRELEF was initially approved by the FDA in May 2021, and we commenced commercial sales in the U.S. in July 2021. In each of December…View ↗
Competes with Pfizer, Fresenius Kabi USA, Pacira BioSciences, Innocoll Pharmaceuticals, Durect, Baudax Bio, Mallinckrodt Pharmaceuticals, Kowa Pharmaceuticals America, Eagle Pharmaceuticals, Takeda Pharmaceutical, Merck &, Helsinn Therapeutics (U.S.), TerSera Therapeutics, Amneal Pharmaceuticals, Cumberland Pharmaceuticals, GlaxoSmithKline, Hoffman-La Roche, Eisai, Helsinn Healthcare, and AVYXA
10-K for FY2025, filed Feb 26, 2026ZYNRELEF competes in the postoperative pain management market with MARCAINETM (bupivacaine hydrochloride injection, solution, marketed by…View ↗
Loading...